SLC5A2 and diabetes mellitus: In conclusion, large placebo-controlled trials of SGLT-2 inhibitors have demonstrated that the relative effects of SGLT-2 inhibitors on mortality and on other key efficacy outcomes are remarkably consistent across the different studied patient groups, and similar in people with and without DM.